The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
Montemurro
Filippo
F
Aglietta
Massimo
M
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016022:Case-Control Studies; D016543:Central Nervous System Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000556:secondary*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D018570:Risk Assessment; D016019:Survival Analysis; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab